GlycoMimetics Inc (GLYC)
0.316
0.00 (0.00%)
USD |
NASDAQ |
Nov 22, 15:47
GlycoMimetics Total Liabilities (Quarterly): 4.322M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 4.322M |
| June 30, 2024 | 4.356M |
| March 31, 2024 | 5.294M |
| December 31, 2023 | 6.902M |
| September 30, 2023 | 6.653M |
| June 30, 2023 | 7.021M |
| March 31, 2023 | 6.740M |
| December 31, 2022 | 8.881M |
| September 30, 2022 | 7.844M |
| June 30, 2022 | 9.317M |
| March 31, 2022 | 13.43M |
| December 31, 2021 | 12.74M |
| September 30, 2021 | 11.38M |
| June 30, 2021 | 12.09M |
| March 31, 2021 | 12.90M |
| December 31, 2020 | 14.61M |
| September 30, 2020 | 12.15M |
| June 30, 2020 | 12.60M |
| March 31, 2020 | 13.61M |
| December 31, 2019 | 13.77M |
| September 30, 2019 | 13.37M |
| June 30, 2019 | 13.78M |
| March 31, 2019 | 11.65M |
| December 31, 2018 | 9.375M |
| Date | Value |
|---|---|
| September 30, 2018 | 7.074M |
| June 30, 2018 | 7.701M |
| March 31, 2018 | 9.382M |
| December 31, 2017 | 8.882M |
| September 30, 2017 | 7.258M |
| June 30, 2017 | 6.190M |
| March 31, 2017 | 5.288M |
| December 31, 2016 | 7.087M |
| September 30, 2016 | 6.259M |
| June 30, 2016 | 6.894M |
| March 31, 2016 | 5.934M |
| December 31, 2015 | 7.991M |
| September 30, 2015 | 7.037M |
| June 30, 2015 | 6.825M |
| March 31, 2015 | 4.104M |
| December 31, 2014 | 6.460M |
| September 30, 2014 | 4.723M |
| June 30, 2014 | 3.636M |
| March 31, 2014 | 2.71M |
| December 31, 2013 | 2.376M |
| September 30, 2013 | 3.046M |
| June 30, 2013 | 1.815M |
| December 31, 2012 | 5.891M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
4.322M
Minimum
Sep 2024
14.61M
Maximum
Dec 2020
9.831M
Average
10.35M
Median
Total Liabilities (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 1.438B |
| Arbutus Biopharma Corp | 33.55M |
| Revance Therapeutics Inc | 624.59M |
| FibroGen Inc | 466.12M |
| Cidara Therapeutics Inc | 46.70M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 15.70M |
| Shareholders Equity (Quarterly) | 11.38M |